Tagrisso with chemo significantly improved survival and progression-free outcomes versus Tagrisso alone in newly diagnosed ...

AstraZeneca's Tagrisso with chemo significantly improves survival and progression-free outcomes in EGFR-mutant NSCLC, final trial data shows.

SCOPE trial of SCIB1/iSCIB1+ plus standard of care shows excellent results encompassing efficacy, durability, immune responses and safety Overall response rate for iSCIB1+ was 69% for target HLA type ...

Subjects in the trial received 80mg of Tagrisso daily in oral tablet form, combined with a chemotherapy regimen.

A new review urges oncology researchers to treat patient-reported outcomes as core trial endpoints — not just secondary stats ...

Q-TWiST may help patients with advanced kidney cancer and their doctors weigh treatment options by focusing on quality of ...

SCOPE is testing administration of intramuscular SCIB1 and intradermal iSCIB1+, which codes for various melanoma antigens ...

Oncolytics Biotech reveals promising survival data for pelareorep, an innovative immunotherapy, showing significant benefits ...

AstraZeneca announces positive results from FLAURA2 phase III trial of Tagrisso plus chemotherapy to treat EGFR-mutated advanced lung cancer: Cambridge, UK Tuesday, July 22, 2025, ...

Scancell has linked iSCIB1+ to a 69% response rate in advanced melanoma, lead | Scancell has linked iSCIB1+ to a 69% response ...

Berlin: Bayer has received marketing authorization from the European Commission in the European Union (EU) for Nubeqa ...

European Union approves Bayer’s Nubeq for patients with advanced prostate cancer: Berlin Tuesday, July 22, 2025, 11:00 Hrs [IST] The European Commission has granted marketing au ...